MedTrace Logo

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

NCT07805356 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-09-04

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).

Conditions

  • Hypoparathyroidism
  • Chronic Hypoparathyroidism

Interventions

DRUG

Encaleret

Oral tablets

DRUG

Placebo

Oral tablets

Sponsors & Collaborators

  • Calcilytix Therapeutics, Inc., a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • Calcilytix Medical Director · Calcilytix Therapeutics, Inc., a BridgeBio company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-01-31
Completion
2033-01-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07805356 on ClinicalTrials.gov